CN112513090A - 结合人il-4r的抗体、其抗原结合片段及其医药用途 - Google Patents
结合人il-4r的抗体、其抗原结合片段及其医药用途 Download PDFInfo
- Publication number
- CN112513090A CN112513090A CN201980050263.4A CN201980050263A CN112513090A CN 112513090 A CN112513090 A CN 112513090A CN 201980050263 A CN201980050263 A CN 201980050263A CN 112513090 A CN112513090 A CN 112513090A
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- antigen
- sequence
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 title claims abstract description 114
- 239000000427 antigen Substances 0.000 title claims abstract description 104
- 108091007433 antigens Proteins 0.000 title claims abstract description 104
- 102000036639 antigens Human genes 0.000 title claims abstract description 104
- 239000012634 fragment Substances 0.000 title claims abstract description 100
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 title claims abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 208000035475 disorder Diseases 0.000 claims abstract description 14
- 230000001404 mediated effect Effects 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 36
- 210000004602 germ cell Anatomy 0.000 claims description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 241001529936 Murinae Species 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 6
- 101000839662 Homo sapiens Immunoglobulin heavy variable 3-48 Proteins 0.000 claims description 6
- 101001008325 Homo sapiens Immunoglobulin kappa variable 2D-29 Proteins 0.000 claims description 6
- 101001047617 Homo sapiens Immunoglobulin kappa variable 3-11 Proteins 0.000 claims description 6
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 6
- 102100028320 Immunoglobulin heavy variable 3-48 Human genes 0.000 claims description 6
- 102100027458 Immunoglobulin kappa variable 2D-29 Human genes 0.000 claims description 6
- 102100022955 Immunoglobulin kappa variable 3-11 Human genes 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 208000026278 immune system disease Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims description 3
- 208000023514 Barrett esophagus Diseases 0.000 claims description 3
- 208000023665 Barrett oesophagus Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 3
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 3
- 208000000592 Nasal Polyps Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- 201000004982 autoimmune uveitis Diseases 0.000 claims description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 3
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- 102220541385 3 beta-hydroxysteroid dehydrogenase/Delta 5->4-isomerase type 1_R71I_mutation Human genes 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 102220473254 Emerin_S49A_mutation Human genes 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 102220472894 Receptor-type tyrosine-protein phosphatase beta_R94K_mutation Human genes 0.000 claims description 2
- 230000009465 prokaryotic expression Effects 0.000 claims description 2
- 102200056122 rs11570605 Human genes 0.000 claims description 2
- 102220290202 rs1555242247 Human genes 0.000 claims description 2
- 102220168074 rs200199102 Human genes 0.000 claims description 2
- 102200017271 rs769452 Human genes 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 241000235058 Komagataella pastoris Species 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 18
- 238000011282 treatment Methods 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 208000026935 allergic disease Diseases 0.000 abstract description 6
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 111
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 111
- 102000004388 Interleukin-4 Human genes 0.000 description 31
- 108090000978 Interleukin-4 Proteins 0.000 description 31
- 229940028885 interleukin-4 Drugs 0.000 description 30
- 230000000694 effects Effects 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 23
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 230000000903 blocking effect Effects 0.000 description 13
- 210000004408 hybridoma Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000009824 affinity maturation Effects 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 101100069857 Caenorhabditis elegans hil-4 gene Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 3
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 238000012270 DNA recombination Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 2
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229950003468 dupilumab Drugs 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 102000055229 human IL4 Human genes 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 101100340761 Homo sapiens IL4R gene Proteins 0.000 description 1
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
结合人IL‑4R的抗体、其抗原结合片段及其医药用途。一种嵌合抗体、人源化抗体，其包含来自结合人IL‑4R的抗体及其抗原结合片段的CDR区，以及包含结合人IL‑4R的抗体及其抗原结合片段的药物组合物，及其作为治疗过敏性疾病药物的用途。一种人源化的结合人IL‑4R的抗体，在制备用于治疗IL‑4R介导的疾病或病症的药物中的用途。
Description
PCT国内申请，说明书已公开。
Claims (19)
- PCT国内申请，权利要求书已公开。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310069400.7A CN115991781A (zh) | 2018-08-24 | 2019-08-23 | 结合人il-4r的抗体、其抗原结合片段及其医药用途 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810971269 | 2018-08-24 | ||
| CN2018109712692 | 2018-08-24 | ||
| CN201811472752 | 2018-12-04 | ||
| CN2018114727522 | 2018-12-04 | ||
| CN2019102213113 | 2019-03-22 | ||
| CN201910221311 | 2019-03-22 | ||
| CN201910401923 | 2019-05-15 | ||
| CN2019104019230 | 2019-05-15 | ||
| PCT/CN2019/102169 WO2020038454A1 (zh) | 2018-08-24 | 2019-08-23 | 结合人il-4r的抗体、其抗原结合片段及其医药用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310069400.7A Division CN115991781A (zh) | 2018-08-24 | 2019-08-23 | 结合人il-4r的抗体、其抗原结合片段及其医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112513090A true CN112513090A (zh) | 2021-03-16 |
| CN112513090B CN112513090B (zh) | 2023-03-10 |
Family
ID=69591987
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310069400.7A Pending CN115991781A (zh) | 2018-08-24 | 2019-08-23 | 结合人il-4r的抗体、其抗原结合片段及其医药用途 |
| CN201980050263.4A Active CN112513090B (zh) | 2018-08-24 | 2019-08-23 | 结合人il-4r的抗体、其抗原结合片段及其医药用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310069400.7A Pending CN115991781A (zh) | 2018-08-24 | 2019-08-23 | 结合人il-4r的抗体、其抗原结合片段及其医药用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210238294A1 (zh) |
| EP (1) | EP3808774A4 (zh) |
| JP (1) | JP7405831B2 (zh) |
| KR (1) | KR20210049792A (zh) |
| CN (2) | CN115991781A (zh) |
| AU (1) | AU2019324403A1 (zh) |
| BR (1) | BR112021002989A2 (zh) |
| CA (1) | CA3105527A1 (zh) |
| MX (1) | MX2021001143A (zh) |
| TW (1) | TWI840399B (zh) |
| WO (1) | WO2020038454A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111996172A (zh) * | 2020-09-08 | 2020-11-27 | 中国食品药品检定研究院 | 一种用于测定il-4靶向治疗性抗体生物学活性的方法 |
| CN114652853B (zh) * | 2020-12-22 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | 抗il-4r抗体-药物偶联物及医药用途 |
| CN116583539A (zh) * | 2020-12-22 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 抗il-4r抗体或其抗原结合片段的复合物及医药用途 |
| TW202340252A (zh) | 2022-01-29 | 2023-10-16 | 大陸商上海盛迪醫藥有限公司 | 糖皮質激素的藥物偶聯物 |
| WO2023215750A2 (en) | 2022-05-02 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity |
| TW202406572A (zh) | 2022-05-02 | 2024-02-16 | 美商再生元醫藥公司 | 抗介白素－４受體（ｉｌ－４ｒ）抗體調配物 |
| WO2024061279A1 (en) * | 2022-09-22 | 2024-03-28 | Biosion Inc. | Recombinant bispecific antibodies targeting tslp and il4r |
| WO2024197119A1 (en) * | 2023-03-22 | 2024-09-26 | Sanofi Biotechnology | Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist |
| CN117924491B (zh) * | 2023-12-22 | 2024-10-18 | 华润生物医药有限公司 | 抗il-4r抗体及其用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107683291A (zh) * | 2015-04-02 | 2018-02-09 | 英特维特国际股份有限公司 | 针对犬白介素‑4受体α的抗体 |
| CN108339118A (zh) * | 2017-01-23 | 2018-07-31 | 瑞阳(苏州)生物科技有限公司 | 治疗或预防阻塞性睡眠呼吸暂停的药物组合物 |
| CN108373505A (zh) * | 2018-04-20 | 2018-08-07 | 北京智仁美博生物科技有限公司 | 抗il-4r抗体及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE16192152T1 (de) | 2000-05-26 | 2020-08-06 | Immunex Corporation | Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| DK2769992T3 (da) * | 2006-10-02 | 2021-03-22 | Regeneron Pharma | Humane antistoffer med høj affinitet for human IL-4-receptor |
| EP2245064B1 (en) * | 2007-12-21 | 2014-07-23 | Medimmune Limited | BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha) |
| PE20150091A1 (es) * | 2012-02-24 | 2015-02-16 | Stem Centrx Inc | Anticuerpos anti-sez6 y metodos de empleo |
| CN110624107A (zh) | 2012-08-21 | 2019-12-31 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂治疗或预防哮喘的方法 |
| BR112017003419A2 (pt) * | 2014-09-03 | 2017-11-28 | Medimmune Ltd | formulação de anticorpo anti-il-4r-alfa estável |
| CN108409860B (zh) * | 2017-02-10 | 2021-10-15 | 三生国健药业（上海）股份有限公司 | 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用 |
-
2019
- 2019-08-23 AU AU2019324403A patent/AU2019324403A1/en active Pending
- 2019-08-23 WO PCT/CN2019/102169 patent/WO2020038454A1/zh unknown
- 2019-08-23 BR BR112021002989-3A patent/BR112021002989A2/pt unknown
- 2019-08-23 EP EP19852040.5A patent/EP3808774A4/en active Pending
- 2019-08-23 US US17/269,449 patent/US20210238294A1/en active Pending
- 2019-08-23 CN CN202310069400.7A patent/CN115991781A/zh active Pending
- 2019-08-23 JP JP2021508304A patent/JP7405831B2/ja active Active
- 2019-08-23 MX MX2021001143A patent/MX2021001143A/es unknown
- 2019-08-23 CN CN201980050263.4A patent/CN112513090B/zh active Active
- 2019-08-23 KR KR1020217004544A patent/KR20210049792A/ko unknown
- 2019-08-23 TW TW108130264A patent/TWI840399B/zh active
- 2019-08-23 CA CA3105527A patent/CA3105527A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107683291A (zh) * | 2015-04-02 | 2018-02-09 | 英特维特国际股份有限公司 | 针对犬白介素‑4受体α的抗体 |
| CN108339118A (zh) * | 2017-01-23 | 2018-07-31 | 瑞阳(苏州)生物科技有限公司 | 治疗或预防阻塞性睡眠呼吸暂停的药物组合物 |
| CN108373505A (zh) * | 2018-04-20 | 2018-08-07 | 北京智仁美博生物科技有限公司 | 抗il-4r抗体及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7405831B2 (ja) | 2023-12-26 |
| EP3808774A4 (en) | 2021-08-18 |
| CN112513090B (zh) | 2023-03-10 |
| CA3105527A1 (en) | 2020-02-27 |
| KR20210049792A (ko) | 2021-05-06 |
| WO2020038454A1 (zh) | 2020-02-27 |
| AU2019324403A1 (en) | 2021-01-28 |
| EP3808774A1 (en) | 2021-04-21 |
| MX2021001143A (es) | 2021-04-12 |
| BR112021002989A2 (pt) | 2021-05-11 |
| CN115991781A (zh) | 2023-04-21 |
| JP2021533792A (ja) | 2021-12-09 |
| TWI840399B (zh) | 2024-05-01 |
| US20210238294A1 (en) | 2021-08-05 |
| TW202023612A (zh) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112513090B (zh) | 结合人il-4r的抗体、其抗原结合片段及其医药用途 | |
| KR102662387B1 (ko) | B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도 | |
| US20240254215A1 (en) | Antibody capable of binding to thymic stromal lymphopoietin and use thereof | |
| EP3753951A1 (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| CN110267989B (zh) | 抗cd40抗体、其抗原结合片段及其医药用途 | |
| EP3683234A1 (en) | Il-6r antibody and antigen binding fragment thereof and medical use | |
| CN116554323B (zh) | 人源化抗il21抗体的开发和应用 | |
| CN108178798B (zh) | pH工程化的NGF抗体及其医药用途 | |
| CN114591434A (zh) | 抗Siglec15抗体及其制备方法和用途 | |
| CN115298216A (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
| WO2019062831A1 (zh) | Il-5抗体、其抗原结合片段及医药用途 | |
| WO2022078490A1 (zh) | 抗erbb3抗体或其抗原结合片段及其医药用途 | |
| RU2779649C1 (ru) | Антитело, связывающее человеческий il-4r, его антигенсвязывающий фрагмент и его медицинское применение | |
| WO2021209066A1 (zh) | 特异性抗原结合分子，其制备方法及医药用途 | |
| RU2825304C2 (ru) | Антитело, способное связываться с тимическим стромальным лимфопоэтином, и его применение | |
| CN115947855A (zh) | 抗cd24抗体的制备及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40045558 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240125 Address after: No. 55 Kangyao South Road, Huangpu District, Guangzhou City, Guangdong Province, 510700 Patentee after: Guangdong Jiangsu Hengrui Medicine Co.,Ltd. Country or region after: China Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd. Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd. Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd. Country or region before: China Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |